Market Overview:
The global hereditary angioedema market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing prevalence of hereditary angioedema, rising awareness about the disease, and technological advancements in the field of diagnosis and treatment. Based on type, the global hereditary angioedema market is segmented into C1 esterase inhibitor, kallikrein inhibitor, and selective bradykinin B2 receptor antagonist. The C1 esterase inhibitor segment is expected to account for the largest share of the global market in 2018. This segment is projected to grow at a CAGR of 7.8% from 2018 to 2030 due to increasing incidence rates of hereditary angioedema caused by mutations in theC1 esterase inhibitor gene across all regions.
Product Definition:
Hereditary angioedema (HAE) is a rare, autosomal dominant genetic disorder that results in a deficiency of C1 esterase inhibitor (C1-INH), an important protein in the body's defense against inflammation. This leads to episodes of swelling, most commonly affecting the face and airways.
C1 Esterase Inhibitor:
C1 esterase inhibitor is an enzyme that inhibits the C-terminal part of the proenkephalin. It has been observed that this inhibitor can inhibit both vascular and nonvascular C-terminal esterase activity with an optimum concentration being 0.5 ng/mL in blood cells.
Kallikrein Inhibitor:
Kallikrein inhibitor is a type of drug that works by decreasing the production of kallikrein, which is an enzyme responsible for causing hereditary angioedema (HAE). Kallikrein inhibitors are used to treat HAE and other related diseases.
Application Insights:
Based on application, the market is segmented into retail pharmacies, hospital pharmacies and online pharmacies. The retail pharmacy held the largest share of over 60.0% in 2017 owing to its ability to provide immediate relief and high treatment success rates. Moreover, this segment also has a higher adoption rate among patients as compared with other methods of medication due to its non-invasive nature.
The online pharmacy sector is anticipated to expand at a lucrative CAGR during the forecast period owing to increasing internet usage by patients suffering from angioedema for seeking medical advice and purchasing drugs from remote locations without visiting hospitals or primary healthcare centers (PHCs). Furthermore, growing awareness about this disorder coupled with easy access to various online resources pertaining health issues is further expected fuel growth during the forecast period 2018 - 2030 ¢â‚¬â€œ especially in developing regions such as Asia Pacific and Middle East & Africa where most of these cases are reported from.
Regional Analysis:
North America accounted for the largest share of the global market in 2017. The presence of a large number of pharmaceutical companies and favorable reimbursement policies are some factors contributing to its growth. For instance, in 2015, Gilead Sciences received approval for Heptaresus from the U.S FDA and EMEA simultaneously which is rare these days as new drugs are approved only after single-entity company launches them globally.
Asia Pacific is expected to be one of the fastest growing regions over the forecast period owing to rising incidences hereditary angioedema cases coupled with increasing awareness about treatment options especially during pregnancy & breastfeeding period among mothers.-Hereditary angioedema can occur at any age but most commonly occurs between 1st and 3rd decades affecting both males & females equally.
Growth Factors:
- Increasing awareness about Hereditary Angioedema (HAE) and its symptoms will drive the growth of the Hereditary Angioedema market.
- The increasing incidence of HAE will also fuel the growth of the Hereditary Angioedema market.
- The development of novel therapies for treating HAE will create opportunities for players in the Hereditary Angioedema market.
- Growing demand for orphan drugs will propel the growth of the Hereditary Angioedema market in developed countries.
- Expansion of distribution channels by key players will provide a boost tothe sales and distribution infrastructure forHereditaryAngiodoemamarketplayers
Scope Of The Report
Report Attributes
Report Details
Report Title
Hereditary Angioedema Market Research Report
By Type
C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist
By Application
Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
By Companies
Pharming Group NV, Takeda, CSL Limited, iBio Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Pharming Group NV
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
218
Number of Tables & Figures
153
Customization Available
Yes, the report can be customized as per your need.
Global Hereditary Angioedema Market Report Segments:
The global Hereditary Angioedema market is segmented on the basis of:
Types
C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pharming Group NV
- Takeda
- CSL Limited
- iBio Inc.
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Pharming Group NV
Highlights of The Hereditary Angioedema Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- C1 Esterase Inhibitor
- Kallikrein Inhibitor
- Selective Bradykinin B2 Receptor Antagonist
- By Application:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hereditary Angioedema Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hereditary angioedema is a rare condition in which the body produces an abnormal amount of blood vessels that can swell and cause pain. The most common symptom is swelling of the face, lips, tongue, or throat.
Some of the major players in the hereditary angioedema market are Pharming Group NV, Takeda, CSL Limited, iBio Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Pharming Group NV.
The hereditary angioedema market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hereditary Angioedema Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hereditary Angioedema Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hereditary Angioedema Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hereditary Angioedema Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hereditary Angioedema Market Size & Forecast, 2020-2028
4.5.1 Hereditary Angioedema Market Size and Y-o-Y Growth
4.5.2 Hereditary Angioedema Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 C1 Esterase Inhibitor
5.2.2 Kallikrein Inhibitor
5.2.3 Selective Bradykinin B2 Receptor Antagonist
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Retail Pharmacies
6.2.2 Hospital Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hereditary Angioedema Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hereditary Angioedema Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 C1 Esterase Inhibitor
9.6.2 Kallikrein Inhibitor
9.6.3 Selective Bradykinin B2 Receptor Antagonist
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Retail Pharmacies
9.10.2 Hospital Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 C1 Esterase Inhibitor
10.6.2 Kallikrein Inhibitor
10.6.3 Selective Bradykinin B2 Receptor Antagonist
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Retail Pharmacies
10.10.2 Hospital Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 C1 Esterase Inhibitor
11.6.2 Kallikrein Inhibitor
11.6.3 Selective Bradykinin B2 Receptor Antagonist
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Retail Pharmacies
11.10.2 Hospital Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 C1 Esterase Inhibitor
12.6.2 Kallikrein Inhibitor
12.6.3 Selective Bradykinin B2 Receptor Antagonist
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Retail Pharmacies
12.10.2 Hospital Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 C1 Esterase Inhibitor
13.6.2 Kallikrein Inhibitor
13.6.3 Selective Bradykinin B2 Receptor Antagonist
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Retail Pharmacies
13.10.2 Hospital Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hereditary Angioedema Market: Competitive Dashboard
14.2 Global Hereditary Angioedema Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pharming Group NV
14.3.2 Takeda
14.3.3 CSL Limited
14.3.4 iBio Inc.
14.3.5 BioCryst Pharmaceuticals, Inc.
14.3.6 Ionis Pharmaceuticals, Inc.
14.3.7 Pharming Group NV
